North America

North America Region Focus Areas

Torreya Partners houses over 25 professionals at our headquarters in
New York. We call on and advise a large number of life sciences clients in the United States and Canada. We are focused on the following areas:

Pharmaceuticals

We are a leading advisor of large and specialty pharmaceutical companies in North America with particularly heavy involvement in commercial-stage asset deals and M&A transactions. MORE »

Biotechnology

We work extensively with development stage biotechnology companies and assist in partnering advisory, M&A and financings. MORE »

Generic Pharma

We are heavily involved in transactions in the generic pharmaceutical sector and have recently worked on projects involving orals, liquids, manufacturing, transdermals and complex formulations. MORE »

Nutritionals / OTC

We have been involved with a number of leading companies in the nutritionals and medical foods areas having helped to complete more than $400 million of financings, alliances and other strategic transactions in this area. MORE »

Life Science Tools

We have extensive experience in the life science tools sector. One of our principals formerly ran Biowhittaker, a leading player in this space. MORE »

Medical Devices

We work extensively with development stage biotechnology companies and assist in partnering advisory, M&A and financings. MORE »

Diagnostics

We are very active in diagnostics working on projects in the area of automated histopathology, automated microscopy, genome sequencing and RNA-based diagnostics. MORE »

Pharma Services

We have been active working with both CRO's, CSO's, manufacturers and providers of drug delivery solutions to pharmaceutical companies. MORE »

Our Activities

Our activities in the United States have spanned all major areas of the country. We have been involved in more than a half dozen projects in Canada as well.

Selected Past Deals

Xoma

Royalty Monetization

$22 million

December 2016

North America

Opiant Pharmaceuticals

Partial Royalty Monetization

$17.5 million

December 2016

North America

Rubicon Research

Equity Sale

$33 million

November 2016

North America

SciDose

Partial Sale of Royalties and Milestones

$40 million

September 2016

North America

IntelgenX

Partial Sale of Royalties and Milestones

$6 million

August 2016

North America

Academic Inventor

Sale of Phase II Enzyme Replacement Royalty

August 2016

North America

Topix Pharmaceuticals

Equity Investment

July 2016

North America

Hikma Pharmaceuticals

Sale of ANDAs

February 2016

North America

H2-Pharma

Sale to ANI Pharmaceuticals

$10 million

February 2016

North America

Undisclosed

Credit Facility

$100 million

February 2016

North America

PhosImmune

Sale to Agenus

$10 million upfront in cash & stock + up to $3

December 2015

North America

Amerigen

Senior Credit Facility

$15 million

December 2015

North America

VistaPharm

Sale to Vertice Pharma (backed by Warburg Pincus)

November 2015

North America

XOMA

Sale of Biologics Manufacturing Facilities to Agenus

$5 million in cash and $1 million in Agenus stock

November 2015

North America

XOMA

Sale of Biodefense Program to Nanotherapeutics

November 2015

North America

IGI Laboratories

Acquisition of Alveda Pharmaceuticals

CAD$ 47 million

October 2015

North America

XOMA

License of Global Rights to Anti-TGF-beta Antibody Program to Novartis

Up to $517 million

October 2015

North America

Crown Laboratories

Senior Term Loan from Hayfin Advisors

$20 million

September 2015

North America

Teva

Sale of 22 generic products to ANI Pharmaceuticals

$25 million

July 2015

North America

ProSolus

Sale to Mission Pharmacal

June 2015

North America

Explore Torreya's activities in other geographies: